Evaluation of Cardiac Safety of Treosulfan-Based Chemotherapy in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

The primary objective of this study is to evaluate the **cardiac safety** of treosulfan chemotherapy administered prior to allogeneic hematopoietic stem cell transplantation in patients diagnosed with **acute myeloid leukemia (AML)** or **myelodysplastic syndrome (MDS)**. This is clinically relevant as it aims to assess the potential cardiac risks associated with treosulfan, which is crucial for ensuring the safety and well-being of patients undergoing this treatment regimen. Understanding the cardiac implications of treosulfan is essential for optimizing pre-transplantation chemotherapy protocols and improving patient outcomes.

The clinical trial involves **subjects** diagnosed with **acute myeloid leukaemia (AML)** or **myelodysplastic syndrome (MDS)** who are undergoing allogeneic hematopoietic stem cell transplantation. The study population includes both male and female participants, with an age range that encompasses young adults to older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The trial aims to gather data on this particular patient group without focusing on any specific lifestyle or demographic factors beyond the general health status related to AML and MDS.

The clinical trial is designed to evaluate the **cardiac safety** of treosulfan chemotherapy administered prior to stem cell transplantation in patients diagnosed with **acute myeloid leukemia (AML)** or **myelodysplastic syndrome (MDS)**. This study is a Phase 3, randomized, double-blind, controlled trial, which aims to provide robust data on the safety profile of the treatment regimen. The trial is expected to span from the estimated recruitment start date of May 31, 2022, to the estimated end date of June 16, 2025, encompassing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. The trial will include multiple follow-up visits to monitor the participants' health status, treatment adherence, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement will vary depending on individual response to treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse events, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial is structured to ensure the safety and well-being of participants while providing valuable insights into the cardiac safety of treosulfan in the specified patient population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on May 31, 2022, with an estimated completion date of June 16, 2025. The efficacy of the intervention will be evaluated using predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The efficacy assessments will be conducted at various timepoints throughout the study duration, adhering to the rigorous standards expected in a Phase 3 clinical trial. The trial's design and execution will align with established clinical protocols to ensure the reliability and validity of the efficacy outcomes.